NCT07284082 The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women
| NCT ID | NCT07284082 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | HIV |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-04-17 |
| Primary Completion | 2030-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2026-04-17 with a primary completion date of 2030-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.
Eligibility Criteria
Inclusion Criteria: * 90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site. Exclusion Criteria: * Women who are not virally suppressed (HIV RNA \>200 copies/mL) * Women who are not on antiretroviral therapy * Women who have a history of hysterectomy or oophorectomy * Women who are receiving treatment for active cancer or tuberculosis
Contact & Investigator
Rebecca Abelman, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07284082 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07284082 currently recruiting?
Yes, NCT07284082 is actively recruiting participants. Contact the research team at rebecca.abelman@ucsf.edu for enrollment information.
Where is the NCT07284082 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07284082 clinical trial?
NCT07284082 is sponsored by University of California, San Francisco. The principal investigator is Rebecca Abelman, MD at University of California, San Francisco. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.